Procter & Gamble Health Limited today announced its financial results for the quarter and fiscal year ended June 30, 2024. The fourth quarter reported sales was Rs. 277 crores, down 5% vs. the previous year, owing to changes in the go-to-market model.

The company reported a Profit (before exceptional items and tax) of Rs. 43 crore for the quarter, down 3% vs a year ago. The exceptional items include impairment charges amounting to Rs. 20 crore.

For the fiscal year ended June 30, 2024, the company recorded sales of Rs. 1,129 crores, down 6% vs. a year ago. Profit (before exceptional items and tax) for the fiscal year ended June 30, 2024 was Rs. 294 crores, down 7% vs a year ago.

Milind Thatte, Managing Director, P&G Health India, commented on the performance, stating, "Our results this quarter reflect the typically seasonality of shipments during this period. In addition, we’ve made choices to strengthenthe execution of our integrated strategy with the deployment of a transformed go-to-market model. We’re confident these changes will deliver superior reach, distribution, retail execution and improve our long-term competitiveness. Our strategy remains anchored on a focused product portfolio where performance is a key driver of brand preference, superiority (across product performance, packaging, brand communication, retail execution and value), constructive disruption and an agile, accountable organization. This integrated strategy continues to guide our efforts to generate sustainable, balanced top- and bottom-line growth and value creation.”

“We continue to navigate the evolving market dynamics with resilience and explore innovative solutions to ensure our trusted, quality brands remain the preferred choice for healthcare professionals and consumers alike”, he added.